Back
Ita Tripathy, MD
Respiratory Research Experience
Asthma
AstraZeneca A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to the Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Patient with Moderate-to-Severe Asthma (VECTOR) Young Adult/Child Asthma
TEVA A Phase 2, Multicenter, Rancomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of
TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma. Adult Asthma
Denali - A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma. Adult/Child Asthma
Novartis - A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients 18 Years of Age With Severe Uncontrolled Asthma. Adult Asthma
Teva/Novum - A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma Adult/Adolescent Asthma
TEVA/Compleware - A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma / Adult Asthma
Cipla - A Multicenter Randomized, Parallel-Group, Placebo-Controlled, 4-week Clinical endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 ug Inhalation Powder With Advair Diskus 100/50 ug in Asthma patients / Adult Asthma
GlaxoSmithKline - Phase IV An open-label study to evaluate correct use and ease of use of the ELLIPTA Dry Powder Inhaler (DPI) in pediatric patients currently receiving inhaled therapy for treatment of their asthma / Pediatric Asthma
West Ward Columbus, Inc/Pharm-Olam International - A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma / Adult/Adolescent Asthma
Novartis - A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of care asthma therapy in patients with uncontrolled asthma / Adult/Adolescent Asthma
Chiesi - An 8-week, randomized, double-blind, placebo and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 3 doses of CHF 718 pMDI (beclomethasone dipropionate) in asthmatic subjects / Adult Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
3M - A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Inhaler and a Symbicort® Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 μg/4.5 μg) in Adult Subjects With Asthma / Adult Asthma
GlaxoSmithKline - A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist / .Adult/Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adolescent/Adult Asthma
Teva - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma /
Adult/Adolescent Asthma
Teva - A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
Teva - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
Teva - A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered (80 or 160 mcg/Day) delivered via Breath Actuated Inhaler (BAI) in Adolesent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
Teva - A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 through 11 Years of Age with Persistent Asthma / Pediatric Asthma
Teva - A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety ofFp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
GSK - A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma / Adult Asthma
GSK - A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents / Adult/Adolescent Asthma
Merck - A Six-week Evaluator-Blind, Randomized, Active controlled evaluation of the effects of three doses of Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) on the HPA axis in asthmatic children 5 to 11 years of age / Peds Asthma Over night
Cephalon - A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/Kg) Treatment in Patients With Moderate to Severe Asthma / Adult Asthma
GSK - A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma / Pediatric Asthma
Merck - A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Fomoterol Furmarate MDI Fixed Dose combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma / Adult/Adolescent Asthma
GlaxoSmithKline - A randomized, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. / Adult/Adosescent Asthma
GlaxoSmithKline - A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, DoseRanging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist. / Adult/Adosescent Asthma
GlaxoSmithKline - A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate (FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents / Adult/Adosescent Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
GlaxoSmithKline - A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry posder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma / Adult Asthma overnight
Novartis - A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg) and mometasone furoate Twisthaler® (400µg) in adosescent and adult patients with persistent asthma. / Asthma
GlaxoSmithKline - A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily in the Evening and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma / Asthma
Medicinova - A Randomized, Single-blind, Placebo-Controlled, Dose Escalation Study Evaluating the Safety and Effects of MN-221 in Subjects Diagonesed with Moderate to Severe Asthma / Asthma (Overnight)
GlaxoSmithKline - A Randomized, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Low-Dose ICS Therapy / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 500mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Moderate-Dose ICS Therapy / Asthma
Medicinova - A randomized, double-blind, placebo-controlled study evaluating the effects of MN-221 in subjects with mild to moderate asthma / Asthma (Overnight)
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
Merck - A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of L-000888839 With Placebo and Concomitant Administration of L-000888839 Plus Montelukast in Adult Patients With Chronic Asthma / Adult Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, Who have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
AstraZeneca - A 12-Week, Randomized, Double-Blind, Double-Dummy Placebo and Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and Adolescents with Asthma / Adult Asthma
Pfizer/Altana Pharma - 12 weeks treatment with 125µg roflumilast versus 250µg roflumilast versus placebo in patients with asthma / Adult Asthma Study
Aventis Pharmaceuticals Inc - “A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120 mg BID in Subjects with Mild to Moderate Persistent Asthma” / Asthma
GlaxoSmithKline - “A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS† Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10 mg QD.” / Adult/Adolescent Asthma
Forest Laboratories, Inc. - “A Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Once-Daily Flunisolide FHA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids” / Asthma
Schering/ Plough - “Placebo-Controlled Efficacy and Safety Study of a Once- Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects With Asthma Who Were Previously Maintained On Inhaled Corticosteroids” / Asthma
Aventis - “A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multiple-Dose Study of the Potential Effects of Ciclesonide and Fluticasone Propionate on HPA-Axis in Adult Asthma Patients” / Adult Asthma
Forest Laboratories, Inc. - “A Double Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma” / Pediatric Asthma
Aventis Pharmaceuticals Inc. - “A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Pilot Study to Observe the Effects of Montelukast 10 mg in Combination with Fexofenadine 180 mg Daily or 120 mg BID on Asthma in Subjects with Persistent Mild to Moderate Atopic Asthma" / Asthma
Bayer Corp. - "A Randomized, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma" / Asthma
Rhone-Poulenc Rorer - “A Phase III, Multicenter, Double-Blind, Parallel Group Study Assessing the Effects of Triamcinolone Acetonide HFA-134a MDI on Growth in Asthmatic Children” / Pediatric Asthma
Novartis - “A Phase III, 7-month Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-Month open-Label extension Period to assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of subcutaneous rhuMAb-E25 in Children (6-12 years) with Allergic Asthma requiring daily treatment with Inhaled Corticosteroids" / Pediatric Asthma
Zeneca Pharmaceuticals - “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Effect of Oral Zafirlukast (ACCOLATEtm) on Growth in Prepubescent Children with Mild-to-Moderate Asthma” / Pediatric Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
3M - A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Inhaler and a Symbicort® Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 μg/4.5 μg) in Adult Subjects With Asthma / Adult Asthma
GlaxoSmithKline - A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and twice daily Fluticasone Propionate 250 mcg Inhalation Powder in the treatment of persistent asthma in adults and adolescents already adequately controlled on twice-daily inhaled corticosteroid and long-acting beta2 agonist / .Adult/Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) at 320 or 640 mcg/day in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adolescent/Adult Asthma
Teva - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma /
Adult/Adolescent Asthma
Teva - A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
Teva - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
Teva - A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered (80 or 160 mcg/Day) delivered via Breath Actuated Inhaler (BAI) in Adolesent and Adult Patients 12 Years of Age and Older with Persistent Asthma / Adult/Adolescent Asthma
Teva - A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 through 11 Years of Age with Persistent Asthma / Pediatric Asthma
Teva - A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety ofFp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy / Adult/Adolescent Asthma
GSK - A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma / Adult Asthma
GSK - A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents / Adult/Adolescent Asthma
Merck - A Six-week Evaluator-Blind, Randomized, Active controlled evaluation of the effects of three doses of Mometasone Furoate/Formoterol Fumarate (MF/F) metered dose inhaler (MDI) on the HPA axis in asthmatic children 5 to 11 years of age / Peds Asthma Over night
Cephalon - A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/Kg) Treatment in Patients With Moderate to Severe Asthma / Adult Asthma
GSK - A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma / Pediatric Asthma
Merck - A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Fomoterol Furmarate MDI Fixed Dose combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma / Adult/Adolescent Asthma
GlaxoSmithKline - A randomized, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents. / Adult/Adosescent Asthma
GlaxoSmithKline - A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, DoseRanging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist. / Adult/Adosescent Asthma
GlaxoSmithKline - A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate (FP)/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents / Adult/Adosescent Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
GlaxoSmithKline - A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry posder inhaler (NDPI) in subjects ≥18 years of age with persistent asthma / Adult Asthma overnight
Novartis - A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg) and mometasone furoate Twisthaler® (400µg) in adosescent and adult patients with persistent asthma. / Asthma
GlaxoSmithKline - A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily in the Evening and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma / Asthma
Medicinova - A Randomized, Single-blind, Placebo-Controlled, Dose Escalation Study Evaluating the Safety and Effects of MN-221 in Subjects Diagonesed with Moderate to Severe Asthma / Asthma (Overnight)
GlaxoSmithKline - A Randomized, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Low-Dose ICS Therapy / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 500mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Moderate-Dose ICS Therapy / Asthma
Medicinova - A randomized, double-blind, placebo-controlled study evaluating the effects of MN-221 in subjects with mild to moderate asthma / Asthma (Overnight)
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
Merck - A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of L-000888839 With Placebo and Concomitant Administration of L-000888839 Plus Montelukast in Adult Patients With Chronic Asthma / Adult Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, Who have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
AstraZeneca - A 12-Week, Randomized, Double-Blind, Double-Dummy Placebo and Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and Adolescents with Asthma / Adult Asthma
Pfizer/Altana Pharma - 12 weeks treatment with 125µg roflumilast versus 250µg roflumilast versus placebo in patients with asthma / Adult Asthma Study
Aventis Pharmaceuticals Inc - “A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120 mg BID in Subjects with Mild to Moderate Persistent Asthma” / Asthma
GlaxoSmithKline - “A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS† Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10 mg QD.” / Adult/Adolescent Asthma
Forest Laboratories, Inc. - “A Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Once-Daily Flunisolide FHA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids” / Asthma
Schering/ Plough - “Placebo-Controlled Efficacy and Safety Study of a Once- Daily PM and Twice Daily Regimens of Mometasone Furoate Administered Via Dry Powder Inhaler in Subjects With Asthma Who Were Previously Maintained On Inhaled Corticosteroids” / Asthma
Aventis - “A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multiple-Dose Study of the Potential Effects of Ciclesonide and Fluticasone Propionate on HPA-Axis in Adult Asthma Patients” / Adult Asthma
Forest Laboratories, Inc. - “A Double Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma” / Pediatric Asthma
Aventis Pharmaceuticals Inc. - “A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Pilot Study to Observe the Effects of Montelukast 10 mg in Combination with Fexofenadine 180 mg Daily or 120 mg BID on Asthma in Subjects with Persistent Mild to Moderate Atopic Asthma" / Asthma
Bayer Corp. - "A Randomized, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma" / Asthma
Rhone-Poulenc Rorer - “A Phase III, Multicenter, Double-Blind, Parallel Group Study Assessing the Effects of Triamcinolone Acetonide HFA-134a MDI on Growth in Asthmatic Children” / Pediatric Asthma
Novartis - “A Phase III, 7-month Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial with a 5-Month open-Label extension Period to assess Safety and Tolerability, Steroid-Reduction, Pharmacokinetics, and Pharmacodynamics of subcutaneous rhuMAb-E25 in Children (6-12 years) with Allergic Asthma requiring daily treatment with Inhaled Corticosteroids" / Pediatric Asthma
Zeneca Pharmaceuticals - “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Effect of Oral Zafirlukast (ACCOLATEtm) on Growth in Prepubescent Children with Mild-to-Moderate Asthma” / Pediatric Asthma
Forest Laboratories, Inc. - “A Long-Term Open Study to Evaluate the Safety of HFA Flunisolide in Adult and Pediatric Patients with Mild to Moderate Asthma” / Pediatric Asthma
Glaxo Wellcome Inc. - “A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma” / Adult/Adolescent Asthma
Glaxo Wellcome Inc. - “A Randomized, Double-Blind, Parallel Group, Comparison Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD), in Subjects Currently Receiving Beta-Agonists Alone” / Asthma
Merck & Co., Inc. - “A Multicenter, Double-Blind, Placebo-Controlled Study of the Clinical Effect of Nebulized L-808, 065 in Patients with Chronic Asthma” / Asthma
Schering-Plough, ITGI - “A Study to Evaluate Subject Preference for Proventil HFA (Albuterol Sulfate Inhalation Aerosol) vs a Generic Albuterol Inhalation Aerosol: A Cross-over Study” / Asthma
Schering Plough - “A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Integrated Therapeutics/Schering - "An Investigator/Evaluator Blinded, Placebo-Controlled Comparison of the Clinical Efficacy and Safety of Beclomethasone Dipropionate Double Strength MDI (672mcg daily) vs. Flovent ™ MDI (704mcg daily) in Subjects with Mild to Moderately Severe Asthma" / Asthma
Zeneca Pharmaceuticals - "A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Zafirlukast (ACCOLATEтм) in Subjects with Mild to Moderate Asthma: 3 Weeks Efficacy and up to 52 Weeks Open-Label Safety Extension" / Asthma
Glaxo Wellcome - "A Double-Blind, Placebo-Controlled Study to Compare the Effects of Inhaled Fluticasone Propionate (100MCG BID or 250MCG BID), Triamcinolone Acetonide (200MCG QID or 400MCG BID) Via the Metered Dose Inhaler and Oral Prednisone 10MG QD on the HPA Axis" / Asthma
Glaxo Wellcome Inc. - “A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma” / Adult/Adolescent Asthma
Glaxo Wellcome Inc. - “A Randomized, Double-Blind, Parallel Group, Comparison Study of Inhaled Fluticasone Propionate (88mcg BID) Versus Montelukast Sodium (10mg QD), in Subjects Currently Receiving Beta-Agonists Alone” / Asthma
Merck & Co., Inc. - “A Multicenter, Double-Blind, Placebo-Controlled Study of the Clinical Effect of Nebulized L-808, 065 in Patients with Chronic Asthma” / Asthma
Schering-Plough, ITGI - “A Study to Evaluate Subject Preference for Proventil HFA (Albuterol Sulfate Inhalation Aerosol) vs a Generic Albuterol Inhalation Aerosol: A Cross-over Study” / Asthma
Schering Plough - “A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Integrated Therapeutics/Schering - "An Investigator/Evaluator Blinded, Placebo-Controlled Comparison of the Clinical Efficacy and Safety of Beclomethasone Dipropionate Double Strength MDI (672mcg daily) vs. Flovent ™ MDI (704mcg daily) in Subjects with Mild to Moderately Severe Asthma" / Asthma
Zeneca Pharmaceuticals - "A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Zafirlukast (ACCOLATEтм) in Subjects with Mild to Moderate Asthma: 3 Weeks Efficacy and up to 52 Weeks Open-Label Safety Extension" / Asthma
Glaxo Wellcome - "A Double-Blind, Placebo-Controlled Study to Compare the Effects of Inhaled Fluticasone Propionate (100MCG BID or 250MCG BID), Triamcinolone Acetonide (200MCG QID or 400MCG BID) Via the Metered Dose Inhaler and Oral Prednisone 10MG QD on the HPA Axis" / Asthma
Allergic Rhinitis Research Experience
Glenmark - A Double-Blind, Randomized Parallell-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Comination GSP 301 nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Glenmark - A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older) / Adult/Adolescent SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis /
Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma. / Peds Rhinoconjunctivitis
Perrigo - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the safety and bioequivalence of Perrigo UK FINCO's Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray 137mcg/50mcg per actuation compared with Meda Pharmaceuticals Inc.'s Dymista® (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137mcg/50mcg per actuation in the relief of seasonal allergic rhinitis (SAR) symptoms. / Adult/Adolescent SAR
GSK - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR). /
Adult SAR
MEDA - "Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages ≥4 years to <12 years with Seasonal Allergic Rhinitis" / Pediatric SAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Novum - A Randomized, Double-blind, Vehicle-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Safety and Bioequivalence of Perrigo Israel Pharmaceuticals, Ltd. Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/actuation Compared with Nasonex® (Mometasone Furoate Monohydrate) Nasal Spray 50 mcg/actuation (Schering Corporation) in the relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)” / Adult Adolescent SAR
Circassia - An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects with a History of Ragweed Allergen-Induced Rhinoconjunctivitis / SAR
Merck - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma / .Pediatric SAR
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older) / Adult Adosescent PAR
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Schering Plough - Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Asssociated With Seasonal Allergic Rhinitis (SAR) / Ragweed
Greer Labs - Parallel, Randomized, Double blind Placebo Controlled Trial in Adults for the Sublingual Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen / SAR
Schering Plough (Observation) - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adults Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / SAR
Schering Plough - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric SAR
Alcon - Safety and Efficacy of Olopatadine HCI Nasal Spray in 6-11 Year Old Patients/ Pediatric SAR
Schering-Plough - Efficacy and Safety of Concurrent Administraion of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spary Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis / SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
GlaxoSmithKline - A Multicenter, No Drug Treatment, Longitudinal Survey Study to Evaluate the Reliability, Validity, and Responsiveness of the Rhinitis control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Yrs of age and Older with Non-Infectious Allergic and Non-Allergic Rhinitis / SAR,PAR,PNAR
Curalogic, A/S - A Randomized, Double-blind, Parallel Group, Placebo-Controlled Study To Assess The Efficacy And Safety Of Oral Microencapsulated Ragweed Pollen Extract Administered Prior To And During The Ragweed Pollen Season / Ragweed SAR
ALK/Abello (GRAZAX) - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Altana Pharma (490) - Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy / PAR
Alcon - Safety Study of Olopatadine Nasal Spray (add on site) / PAR
ITGI - A Double-blind, Placebo-controlled, Randomized, Parallel-group Mutlicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in subjects with Symptomatic Seasonal Allergic Rhinitis / Fall Allergy
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
Altana - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinits (SAR) in Patients 6 to 11 Years of Age / Pediatric SAR
Apotex/AAI - A Bioequivalence study of 200 mcg of mometasone furoate nasal spray (Apotex Inc., Canada) vs. 200 mcg of Nasonex® nasal spray (Schering Corporation, USA) in patients with seasonal allergic rhinitis / Fall SAR
GlaxoSmithKline, Inc. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intrannasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 2 weeks in Adult and Adolescent Subjects ≥12 Years of Age with Seasonal Allergic Rhinitis (SAR) / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 weeks in Pedicatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis(SAR) / Pediatric SAR
GlaxoSmithKline - A Randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of SW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adreocortical (HPA) axis in pediatric subjects 2 to <12 years of agew with perennial allergic rhinitis (PAR) / Pediatric PAR
Apotex, Inc. - A Bioequivalence Study of 200mcg of Fluticasone Propionate Nasal Spray (Apotex Inc., Canada) vs. 200mcg of Flonase® Nasal Spray (GlaxoSmithKline, USA) in Patients with Seasonal Allergic Rhinitis / Adult SAR
ITGI, Inc. - Efficay and Safety of Desloratadine, Fexofenadine 180 mg. and Placebo in the Treatment of Subjects with Symptomatic Seasonal allergic Rhinitis (SAR) / Adult SAR
DYNAVAX Technologies Corp. - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
DYNAVAX Technologies Corp. - A Phase I Observer-blind, Randomized, Placebo-Controlled Study of the Tolerability and Immunogenicity of Subcutaneously administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Children / Ragweed-Allergic Children
Merck & Co., Inc. - A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast verses Placebo During the Allergy Season in Patients with Seasonal aeroallergen sensitivity / Adult Asthma/SAR
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Merck - A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of L-000888839 in
Patients With Seasonal Allergic Rhinitis-a Pilot Study During the Fall Season / Adult Fall SAR
Glaxo SmithKline - A Multi-Center,Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in
Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiveing Concurrent Open-Lable Advair Diskus 100/50 mcg BID. / Asthma and SAR
Integrated Therapeutics Group, Inc. - Asthma-SARP03280-06 Efficacy and Safety of Nasonex vs. Placebo in Subjects with SAR and
concomitant Asthma / Asthma SAR
Aventis Pharmaceuticals Inc - “A multi-Center, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 12mg Bid, fexotenadine 240mg OQ, and placebo in subjects with perennial allergic rhinitis” / PAR
Allergenics - “A Phase IIb Parallel Group, Placebo Controlled Study of Two Different Maintenance Doses of Orally Administered Microencapsulated Ragweed Pollen Extract” / Ragweed Pollen Extract
Merck & Co., Inc. - “ A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis ” / PAR
Merck & Co., Inc. - “ A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001” / SAR
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort (80/4.5mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma.” / Adult/Pediatric SAR
Roxane - “A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionate Aqueous Nasal Spray Versus FLONASE® Nasal Spray Versus Placebo Basal Spray in Subjects with Seasonal Allergic Rhinitis.” / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis" / SAR
Schering-Plough Research Institute - "Efficacy and Safety of Desloratadine 5 mg Tablet in the Treatment of Subjects 12 to 17 Years of Age with Seasonal Allergic Rhinitis" / Adolescent SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis, Fall Study" / SAR
Aventis Pharmaceuticals, Inc - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCL 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis" / Pediatric Allergic Rhinitis
Hoechst Marion Roussel - “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCI Tablets 30 mg Twice a Day in Pediatric Subjects (6 to 11 years) in the Treatment of Seasonal Allergic Rhinitis” / Pediatric SAR
Merck & Co. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis” / SAR
Glenmark - A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older) / Adult/Adolescent SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis /
Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma. / Peds Rhinoconjunctivitis
Perrigo - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the safety and bioequivalence of Perrigo UK FINCO's Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray 137mcg/50mcg per actuation compared with Meda Pharmaceuticals Inc.'s Dymista® (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137mcg/50mcg per actuation in the relief of seasonal allergic rhinitis (SAR) symptoms. / Adult/Adolescent SAR
GSK - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR). /
Adult SAR
MEDA - "Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages ≥4 years to <12 years with Seasonal Allergic Rhinitis" / Pediatric SAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Novum - A Randomized, Double-blind, Vehicle-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Safety and Bioequivalence of Perrigo Israel Pharmaceuticals, Ltd. Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/actuation Compared with Nasonex® (Mometasone Furoate Monohydrate) Nasal Spray 50 mcg/actuation (Schering Corporation) in the relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)” / Adult Adolescent SAR
Circassia - An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects with a History of Ragweed Allergen-Induced Rhinoconjunctivitis / SAR
Merck - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma / .Pediatric SAR
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Teva - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older) / Adult Adosescent PAR
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Schering Plough - Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Asssociated With Seasonal Allergic Rhinitis (SAR) / Ragweed
Greer Labs - Parallel, Randomized, Double blind Placebo Controlled Trial in Adults for the Sublingual Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused by Ragweed Pollen / SAR
Schering Plough (Observation) - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adults Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / SAR
Schering Plough - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric SAR
Alcon - Safety and Efficacy of Olopatadine HCI Nasal Spray in 6-11 Year Old Patients/ Pediatric SAR
Schering-Plough - Efficacy and Safety of Concurrent Administraion of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spary Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis / SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
GlaxoSmithKline - A Multicenter, No Drug Treatment, Longitudinal Survey Study to Evaluate the Reliability, Validity, and Responsiveness of the Rhinitis control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Yrs of age and Older with Non-Infectious Allergic and Non-Allergic Rhinitis / SAR,PAR,PNAR
Curalogic, A/S - A Randomized, Double-blind, Parallel Group, Placebo-Controlled Study To Assess The Efficacy And Safety Of Oral Microencapsulated Ragweed Pollen Extract Administered Prior To And During The Ragweed Pollen Season / Ragweed SAR
ALK/Abello (GRAZAX) - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Altana Pharma (490) - Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy / PAR
Alcon - Safety Study of Olopatadine Nasal Spray (add on site) / PAR
ITGI - A Double-blind, Placebo-controlled, Randomized, Parallel-group Mutlicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in subjects with Symptomatic Seasonal Allergic Rhinitis / Fall Allergy
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
Altana - A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinits (SAR) in Patients 6 to 11 Years of Age / Pediatric SAR
Apotex/AAI - A Bioequivalence study of 200 mcg of mometasone furoate nasal spray (Apotex Inc., Canada) vs. 200 mcg of Nasonex® nasal spray (Schering Corporation, USA) in patients with seasonal allergic rhinitis / Fall SAR
GlaxoSmithKline, Inc. - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intrannasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 2 weeks in Adult and Adolescent Subjects ≥12 Years of Age with Seasonal Allergic Rhinitis (SAR) / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 weeks in Pedicatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis(SAR) / Pediatric SAR
GlaxoSmithKline - A Randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of SW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adreocortical (HPA) axis in pediatric subjects 2 to <12 years of agew with perennial allergic rhinitis (PAR) / Pediatric PAR
Apotex, Inc. - A Bioequivalence Study of 200mcg of Fluticasone Propionate Nasal Spray (Apotex Inc., Canada) vs. 200mcg of Flonase® Nasal Spray (GlaxoSmithKline, USA) in Patients with Seasonal Allergic Rhinitis / Adult SAR
ITGI, Inc. - Efficay and Safety of Desloratadine, Fexofenadine 180 mg. and Placebo in the Treatment of Subjects with Symptomatic Seasonal allergic Rhinitis (SAR) / Adult SAR
DYNAVAX Technologies Corp. - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
DYNAVAX Technologies Corp. - A Phase I Observer-blind, Randomized, Placebo-Controlled Study of the Tolerability and Immunogenicity of Subcutaneously administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Children / Ragweed-Allergic Children
Merck & Co., Inc. - A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast verses Placebo During the Allergy Season in Patients with Seasonal aeroallergen sensitivity / Adult Asthma/SAR
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Merck - A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of L-000888839 in
Patients With Seasonal Allergic Rhinitis-a Pilot Study During the Fall Season / Adult Fall SAR
Glaxo SmithKline - A Multi-Center,Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200 mcg QD versus Montelukast 10 mg QD in
Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiveing Concurrent Open-Lable Advair Diskus 100/50 mcg BID. / Asthma and SAR
Integrated Therapeutics Group, Inc. - Asthma-SARP03280-06 Efficacy and Safety of Nasonex vs. Placebo in Subjects with SAR and
concomitant Asthma / Asthma SAR
Aventis Pharmaceuticals Inc - “A multi-Center, double-blind, randomized, parallel study comparing the efficacy and safety of fexofenadine 12mg Bid, fexotenadine 240mg OQ, and placebo in subjects with perennial allergic rhinitis” / PAR
Allergenics - “A Phase IIb Parallel Group, Placebo Controlled Study of Two Different Maintenance Doses of Orally Administered Microencapsulated Ragweed Pollen Extract” / Ragweed Pollen Extract
Merck & Co., Inc. - “ A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis ” / PAR
Merck & Co., Inc. - “ A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001” / SAR
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort (80/4.5mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma.” / Adult/Pediatric SAR
Roxane - “A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionate Aqueous Nasal Spray Versus FLONASE® Nasal Spray Versus Placebo Basal Spray in Subjects with Seasonal Allergic Rhinitis.” / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients with Seasonal Allergic Rhinitis" / SAR
Schering-Plough Research Institute - "Efficacy and Safety of Desloratadine 5 mg Tablet in the Treatment of Subjects 12 to 17 Years of Age with Seasonal Allergic Rhinitis" / Adolescent SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis, Fall Study" / SAR
Aventis Pharmaceuticals, Inc - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCL 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis" / Pediatric Allergic Rhinitis
Hoechst Marion Roussel - “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of Oral Fexofenadine HCI Tablets 30 mg Twice a Day in Pediatric Subjects (6 to 11 years) in the Treatment of Seasonal Allergic Rhinitis” / Pediatric SAR
Merck & Co. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis” / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis who have a History of Asthma” 102-00 / SAR
Glaxo Wellcome - “A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Assess the Potential Growth Effects of a One-Year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis” / Pediatric PAR
WIRB 990666 - “Efficacy and Safety of SCH 34117 in the Prophylaxis of Subjects with Seasonal Allergic Rhinitis” / SAR
Novartis - “A Phase IIIB, Multicenter, Multiple Dose, 4-month, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of rhuMAb-E25 for the Treatment of Symptomatic Patients 12-75 Years Old with Perennial Allergic Rhinitis” / Adult/Adolescent PAR
Schering Plough - “Comparative Efficacy and Safety of Nasonex (Mometasone Furoate Monohydrate) Nasal Spray vs Flonase (Fluticasone Propionate) Nasal Spray vs Placebo in Subjects with Seasonal Allergic Rhinitis" / SAR
UCB Pharma Inc. - “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Comparing the Efficacy of Three Doses (4mg, 15mg, or 60mg) of usb 28745 (efletirizine dihydrochloride). Administered Twice a Day for 7 Days to Placebo in Adult Outpatients with Seasonal Allergic Rhinitis caused by Ragweed Pollen.” / Adult SAR
Schering-Plough - “A Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of Claritin® vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis” / SAR
Integrated Therapeutics/Schering - "A Prospective Study to Evaluate the Clinical and Pharmacoeconomic Benefits of Vancenase AQ DS in Patients with Allergic Rhinitis Having a History of Sinusitis" / Allergic Rhinitis
Integrated Therapeutics/ Schering - "Safety and Efficacy of Claritin-D 24 Hour vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis (SAR)" / SAR
Glaxo Wellcome - "Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus a Combination of Fluticasone and Loratadine Versus Placebo for Two Weeks in Subjects with Seasonal Allergic Rhinitis" / SAR
Schering Corporation - "Dose Ranging Study of Mometasone Furoate Nasal Spray in the Treatment of Children (Ages 6-11) with Seasonal Allergic Rhinitis" / Peds SAR
Glaxo Wellcome - "A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fluticasone Propionate Aqueous Nasal Spray Versus Placebo Followed by a One Year Open-label Safety Extension in Subjects with Perennial Non-allergic Rhinitis" / PAR
Glaxo Wellcome - “A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Assess the Potential Growth Effects of a One-Year Course of Fluticasone Propionate Aqueous Nasal Spray (200mcg QD) Versus Placebo in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis” / Pediatric PAR
WIRB 990666 - “Efficacy and Safety of SCH 34117 in the Prophylaxis of Subjects with Seasonal Allergic Rhinitis” / SAR
Novartis - “A Phase IIIB, Multicenter, Multiple Dose, 4-month, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of rhuMAb-E25 for the Treatment of Symptomatic Patients 12-75 Years Old with Perennial Allergic Rhinitis” / Adult/Adolescent PAR
Schering Plough - “Comparative Efficacy and Safety of Nasonex (Mometasone Furoate Monohydrate) Nasal Spray vs Flonase (Fluticasone Propionate) Nasal Spray vs Placebo in Subjects with Seasonal Allergic Rhinitis" / SAR
UCB Pharma Inc. - “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Comparing the Efficacy of Three Doses (4mg, 15mg, or 60mg) of usb 28745 (efletirizine dihydrochloride). Administered Twice a Day for 7 Days to Placebo in Adult Outpatients with Seasonal Allergic Rhinitis caused by Ragweed Pollen.” / Adult SAR
Schering-Plough - “A Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of Claritin® vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis” / SAR
Integrated Therapeutics/Schering - "A Prospective Study to Evaluate the Clinical and Pharmacoeconomic Benefits of Vancenase AQ DS in Patients with Allergic Rhinitis Having a History of Sinusitis" / Allergic Rhinitis
Integrated Therapeutics/ Schering - "Safety and Efficacy of Claritin-D 24 Hour vs. Fexofenadine vs. Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis (SAR)" / SAR
Glaxo Wellcome - "Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus a Combination of Fluticasone and Loratadine Versus Placebo for Two Weeks in Subjects with Seasonal Allergic Rhinitis" / SAR
Schering Corporation - "Dose Ranging Study of Mometasone Furoate Nasal Spray in the Treatment of Children (Ages 6-11) with Seasonal Allergic Rhinitis" / Peds SAR
Glaxo Wellcome - "A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fluticasone Propionate Aqueous Nasal Spray Versus Placebo Followed by a One Year Open-label Safety Extension in Subjects with Perennial Non-allergic Rhinitis" / PAR
Device study
AstraZeneca - A 12-week, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy safety, and patient use (user study) of Symbicaort® breath (budesonide/formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5µ twice daily compared with Symbicort (budesonide/formaoterol) AC (actuation counter) pMDI ® 2x160/4.5 µ twice daily and budesonide AC pMDI 2x160 µ twice daily in adult and adolescent asthmatics / Asthma (device study)
GlaxoSmithKline - An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma / Adult/Asthma Device Study
GlaxoSmithKline - An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma / Adult/Asthma Device Study
Allergy/Asthma
GlaxoSmithKline - A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID /Asthma/Allergy
Merck/i3 - Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma which is also Active During allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity / Pediatric Allergy/Asthma
GlaxoSmithKline - A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID /
Asthma/Allergy
Sepracor - “A Double Blind, Placebo-Controlled Study Of Tecastemizole In Subjects With Seasonal and/or Perennial Allergic Rhinitis And Concomitant Asthma” / Asthma/PAR/SAR
Schering-Plough - “Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma” / Asthma/SAR
ITGI/Schering Plough - “A Double-Blind Placebo-controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in subjects with Co-morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)," P97-293 Integrated Therapeutics Group, Inc., A Subsidiary of Schering-Plough Corp. / SAR/Asthma
Merck/i3 - Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma which is also Active During allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity / Pediatric Allergy/Asthma
GlaxoSmithKline - A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID /
Asthma/Allergy
Sepracor - “A Double Blind, Placebo-Controlled Study Of Tecastemizole In Subjects With Seasonal and/or Perennial Allergic Rhinitis And Concomitant Asthma” / Asthma/PAR/SAR
Schering-Plough - “Efficacy and Safety of SCH 34117 in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma” / Asthma/SAR
ITGI/Schering Plough - “A Double-Blind Placebo-controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in subjects with Co-morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)," P97-293 Integrated Therapeutics Group, Inc., A Subsidiary of Schering-Plough Corp. / SAR/Asthma
Chronic Idiopathic Urticaria
ITGI - A Comparitive Double-Blind, Double-Dummy Study of Desloratadine (DL) 5mg Once Daily, Cetirizine 10mg Once Daily, and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (DIU) / Chronic Idiopathic Urticaria
Pediatric Cold/Allergy study
Boehrigner Ingleheim Pharm. - A phase IV Safety Trial in Pediatric Patients (Ages 2-5) with Rhinorrhea Associated with a Common Cold or Allergy / Pediatric Cold/allergy study
Chronic Pruritus
Menlo Therapeutics Inc. - A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin / Pruritus
Allergy Sinus
Whitehall-Robins Healthcare Inc. - “Advil Multi-Symptom Allergy Sinus Efficacy and Safety Study.” / Allergy Sinus